Reckitt Bids Up Bayer With $1.4 Bil. Schiff Nutrition Offer
This article was originally published in The Tan Sheet
Reckitt Benckiser’s $1.4 billion offer to acquire Schiff Nutrition would be 23.5% higher than Bayer’s and more than an 80% premium over Schiff’s share price prior to the Bayer announcement. Gaining Schiff would expand Reckitt’s consumer health business beyond OTC drugs and represent its first supplement foray.
You may also be interested in...
Six months after becoming a wholly owned subsidiary of Procter & Gamble, dietary supplement firm New Chapter is taking advantage of its parent company’s resources in innovation, ingredient sourcing, clinical trials and packaging, says New Chapter VP Graham Rigby.
Reckitt Benckiser reorganizes to emphasize consumer healthcare and emerging markets, both high growth areas for the firm. The firm’s fiscal 2011 total net revenues were $15 billion, driven by emerging markets and brands including Mucinex decongestants, Nurofen analgesics and Strepsils sore throat treatments.
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.